Conclusions In this first paper to compare the rate of new onset uveitis across the three main anti-TNF therapies used in JIA, a new diagnosis of uveitis is less common among patients starting biologics compared with MTX, although this did not reach statistical significance.
← all excerpts
The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.
1
—
—